first-in-class ketohexokinase (KHK) inhibitor oral candidate in Ph. II for NAFLD/NASH from frag.-based screening, SBDD, and opt. J. Med. Chem., Sep. 27, 2020 Pfizer, Cambridge, MA / Groton, CT